Prostate Cancer Interacts With Comorbidity to Increase VTE RateLast Updated: July 20, 2015. For men with prostate cancer, the rate of venous thromboembolism is increased with high comorbidity, according to a study published online July 6 in Cancer.
MONDAY, July 20, 2015 (HealthDay News) -- For men with prostate cancer (PC), the rate of venous thromboembolism (VTE) is increased with high comorbidity, according to a study published online July 6 in Cancer.
Anne G. Ording, Ph.D., from the Aarhus University Hospital in Denmark, and colleagues calculated VTE rate ratios in a nationwide, registry-based cohort study of 44,035 Danish patients diagnosed with PC from 1995 to 2011 and 213,810 men from the general population, matched for age, calendar time, and comorbidities. The authors examined whether comorbidity interacts with PC to increase the VTE rate.
The researchers found that during five years of follow-up, 849 men from the PC cohort and 2,360 from the general population had VTE, with a risk of VTE of 2.2 and 1.3 percent, respectively. Among PC patients with high comorbidity levels, the one-year VTE standardized rate was 15 per 1,000 person-years; an interaction between PC and comorbidity accounted for 29 percent of that rate. Older patients, those with metastases, those with high Gleason scores, those in the D'Amico high-risk group, and those who underwent surgery had increased VTE risk.
"PC interacted clinically with high comorbidity levels and increased the VTE rate," the authors write. "Because of the large population burden of PC, a small reduction in the VTE risk associated with comorbidity may have a positive impact on the prognosis of patients with PC."
The study was partially funded by the Novo Nordisk Foundation.
|Previous: Macrolide-Resistant M. pneumoniae in All U.S. Regions||Next: BMI Doesn’t Affect Kidney Transplant Survival|
Reader comments on this article are listed below. Review our comments policy.